anti-obesity drugs and lipids: what do we know? · anti-obesity drugs and lipids: what do we know?...
TRANSCRIPT
Anti-Obesity Drugs and Lipids: What Do We Know?
Pamela B. Morris, MDFACC, FACP, FACPM, FAHA, FNLA
Director, Preventive CardiologyCo-Director, Women’s Heart Care
Medical University of South CarolinaCharleston, South Carolina
Disclosures
Speakers Bureau
Merck, Genzyme, Aegerion, Abbott, Liposcience
Objectives
To briefly review the effects of diet and exercise on lipids and lipoproteins
To understand the effects of currently approved anti-obesity agents on lipids and lipoproteins
To review anti-obesity agents in development and effects on lipids and lipoproteins
Relationship of BMI to prevalence of metabolic diseases
Journal of Clinical Lipidology 2013; 7:304-383
NHANES 1999-2002
• Dyslipidemias are the most common comorbidities associated with increased body weight.
(TC>240 mg/dl, LDL-C>160 mg/dl, HDL-C<40 mg/dl, TG>200 mg/dl)
BMI and lipid risk factors for men in FOS
Journal of Clinical Lipidology 2013; 7:304-383
• LDL-C is positively but weakly related to LDL-C in men and women—at higher BMI correlation is no longer evident
• Strongest relationship is in lower BMI range
BMI and LDL composition in the MESA Study
Journal of Clinical Lipidology 2013; 7:304-383
• Individuals with high LDL-P were significantly more obese.
• Increase BMI associated with fewer molecules of cholesterol per LDL particle (cholesterol-depleted).
LIPID AND LIPOPROTEIN EFFECTS OF ANTI-OBESITY MANAGEMENT STRATEGIES
Diet Exercise Anti-obesity drugs Lorcaserin Phentermine Phentermine and topiramate extended-release Orlistat (Bupropion SR and naltrexone SR) (Liraglutide)
Lipids and Weight Loss: Diet
NLA Consensus Statement
Extent of weight loss: Varies considerably from 0->10 kg. Higher protein/lower carbohydrate diets often promote greater weight loss at
6 months, at one year magnitude of weight loss is similar
Extent of TG reduction: Most responsive lipid parameter to nutritional/exercise intervention Response depends on baseline TG level (higher, greater response) Greater weight loss, greater reduction Greater reduction with lower carbohydrate diet
Journal of Clinical Lipidology 2013; 7:304-383
Lipids and Weight Loss: Diet
NLA Consensus Statement
Extent of LDL-C reduction:
Higher protein/lower carb diet—LDL-C may increase temporarily followed by eventual decrease as weight loss continues
Lower protein/higher carb diet—more immediate reduction in LDL-C (and HDL-C) that stabilizes over time
During weight maintenance phase when diet is more liberal (calories, SFA), LDL-C trends upward
Journal of Clinical Lipidology 2013; 7:304-383
Lipids and Weight Loss: Diet NLA Consensus Statement
Extent of HDL-C improvement:
HDL-C response varies, affected by dietary intervention and amount of weight loss
Higher protein/lower carb diet—HDL-C may increase temporarily followed by eventual decrease as weight loss continues
Lower protein/higher carb diet—reduction or no change in HDL-C
HDL-C may decrease during active weight loss phase but increase above baseline after weight loss maintained
Journal of Clinical Lipidology 2013; 7:304-383
Lipids and Weight Loss: Diet Summary of effects of diet
Weight loss of 4.5 kg (~10 lbs) would be expected to:
Decrease TC by ~9 mg/dl Decrease LDL-C by ~4 mg/dl Increase HDL-C by 1.6 mg/dl during weight maintenance Decrease TG by 6 mg/dl
Lipid changes with nutritional weight loss are modest and highly variable.
Journal of Clinical Lipidology 2013; 7:304-383
Lipids and Weight Loss: Exercise
Exercise and lipids/lipoproteins
Wide variation in lipid responses to exercise training Some studies show 4-7% reduction in LDL-C, 4-25% increase in HDL-C,
fasting TG reductions 4-37% (mean 24%) Reduction in LDL-P
Fat weight reduction usually required for favorable lipid response
Exercise volume is of primary importance (optimally 250-300 min/wk)
Journal of Clinical Lipidology 2013; 7:304-383
History of Anti-Obesity Drugs
Drug Mechanism of Action Side Effects Comments
Phentermine • Increases the release of noradrenaline, dopamine and serotonin
• Cardiovascular: elevation in BP tachycardia
• CNS: insomnia, restlessness, alters sexual behavior, hormonal secretion and mood
• Approved by the FDA in 1959
• Recommended for short-term use (less than 3 months)
Orlistat • Gastrointestinal lipase inhibitor
• Steatorrhea, fecal incontinence, flatulence,and malabsorption of fat soluble vitamins
• Rare cases of severe liver injury
• Potential risk of kidney injury
• Approved by the FDA in 1999
Lorcaserin • 5-HT 2c receptor agonist that is more specific than previous compounds (eg, fenfluramine)
• Headache, dizziness, nausea, valvulopathy
• Approved by the FDA in June 2012
• Under evaluation by the EMA
• Post-marketing, long-term cardiovascular outcomes trial required
Phentermine/topiramateextended-release
• Phentermine mechanism of action as above
• Topiramate: anticonvulsant, precise mechanism of action unknown
• Possible teratogeniceffects with topiramate
• Can increase heart rate
• Approved by the FDA in July 2012
• Post-marketing, long-term cardiovascular outcomes trial required
Journal of Clinical Lipidology 2013; 7:304-383
Drugs withdrawn Mechanism of Action Side Effects Comments
Fenfluramine • Increases the release of serotonin
• Serotonin re-uptake inhibitor
• Hallucinations, valvulopathy, pulmonaryhypertension
• Approved by the FDA in 1973
• Withdrawn in 1997
Sibutramine • Noradrenalin and serotoninre-uptake inhibitor
• Increased risk of MI and CVA in patients with high risk of CVD
• Approved by the FDA in 1997
• Withdrawn in 2010
Rimonabant • Cannabinoid 1 receptor antagonist
• Risk of suicide • Approved by the EMA in 2006
• Withdrawn in 2009
Awaiting decision
Bupropion SR/NaltrexoneSR
• Bupropion: inhibitor of dopamine and noradrenalin uptake
• Naltrexone: opioid receptor antagonist
• Nausea, constipation, vomiting, dry mouth
• Potential CVD risk
• FDA will not approve without CVD outcomesassessment, trial in progress
Under investigation
Liraglutide • Human glucagon-like peptide-1 analog
• GI side effects (nausea,constipation, diarrhea, vomiting)
• Phase III trials completed and in progress
• Regulatory filings in EU and US expected in 2014
Journal of Clinical Lipidology 2013; 7:304-383
LORCASERIN
LorcaserinLorcaserin
Class of agent • Approved for weight management in June 2012
Mechanism(s) of action • Serotonin 5-hydroxytryptamine 2c receptor agonist which may increase satiety
• (5-HT 2b implicated in valvulopathy)
• Little evidence to support increased energy expenditure
Potential adverse effects • Headache, dizziness, fatigue, nausea, dry mouth, constipation, cough, reduced heart rate, hyperprolactinemia
JCL, 2013;7:304-383
Lorcaserin DOSAGE AND ADMINISTRATION
• One tablet of 10 mg twice daily• Discontinue if 5% weight loss is not achieved by week 12
DOSAGE FORMS AND STRENGTHS10 mg film-coated tablets
CONTRAINDICATIONSPregnancy category X
Lorcaserin
Avoided REMS program
FDA is mandating a long-term cardiovascular outcomes trial that will finish in 2018 (begins mid-2013).
Lorcaserin Three sentinel phase 3 lorcaserin trials
Behavior Modification and Lorcaserin for Overweight and Obesity Management (BLOOM) trial
Behavior Modification and Lorcaserin Second Study for Obesity Management (BLOSSOM) trial
Behavior Modification and Lorcaserin for Overweight and Obesity Management in Diabetes Mellitus (BLOOM-DM) trial
BLOOM Study Multicenter, Placebo-controlled Trial of Lorcaserin for
Weight Management
3182 obese/overweight adults (83% female, 67% white, mean age 44 yr)
Randomized to lorcaserin 10 mg BID vs placebo for 52 weeks (weight loss phase) with lifestyle counseling
Lorcaserin group randomly reassigned at 1 year to continue lorcaserin or change to placebo (maintenance of weight loss phase)
Smith SR et al. N Engl J Med 2010;363:245-256.
Baseline Characteristics of the Patients, According to Study Group
Smith SR et al. N Engl J Med 2010;363:245-256.
Effects of Lorcaserin on Body Weight, According to Study Group
Smith SR et al. N Engl J Med 2010;363:245-256.
47.5%20.3%
22.6%
7.7%
2.2 + 0.1 kg vs5.8 + 0.2 kg
Net: 3.6 kg
Changes in Efficacy and Safety End Points between Baseline and 1 Year.
Smith SR et al. N Engl J Med 2010;363:245-256.
Improvements reduced in both groups by year 2
%
BLOSSOM Trial
A One-Year Randomized Trial of Lorcaserin for Weight Loss in Obese and Overweight Adults: The BLOSSOM Trial
4008 patients, 18-65 yo, 79.8% female
Excluded diabetics
Randomized 2:1:2 to receive lorcaserin 10 mg BID, lorcaserin 10 mg QD, or placebo with lifestyle counseling
J Clin Endocrinol Metab, 2011; 96:3067-3077
Body weight change from baseline to wk 52
Fidler M C et al. JCEM 2011;96:3067-3077
Net 2.9 kg weight loss
with BID dosing
BLOSSOM TrialLorcaserin10 mg BID,
n = 1561
Lorcaserin 10 mg QD,
n = 771
Placebo, n = 1541
P vs. placeboa
BID QD
Patients achieving ≥5% weight loss [n (%)] 737 (47.2) 310 (40.2)b 385 (25.0) <0.001 <0.001
Patients achieving ≥10% weight loss [n (%)]
353 (22.6) 134 (17.4)b 150 (9.7) <0.001 <0.001
Body weight
Baseline (kg) 100.3 (15.7) 100.1 (16.7) 100.8 (16.2)
Change (kg) −5.8 (6.4) −4.7 (6.4)b −2.9 (6.4) <0.001 <0.001
Change (%) −5.8 (6.3)* −4.7 (6.3)b −2.8 (6.3) <0.001 <0.001
J Clin Endocrinol Metab, 2011; 96:3067-3077*Identical to weight loss in BLOOM Study
BLOSSOM TrialTotal cholesterol (mg/dl) Lorcaserin
10 mg BIDLorcaserin10 mg QD Placebo P vs. placebo
BIDP vs. placebo
QD
Baseline 194.2 (37.5) 194.8 (37.8) 193.1 (36.8)
% change −0.7 (13.0) −1.3 (13.0) 0.0 (13.0) NS 0.03
LDL-C (mg/dl)
Baseline 116.3 (32.0) 116.7 (32.0) 114.8 (29.9)
% change 0.3 (19.7) −0.1 (19.7) 1.7 (19.7) NS NS
HDL-C (mg/dl)
Baseline 51.5 (12.9) 51.8 (13.6) 51.3 (13.2)
% change 3.7 (15.4) 3.5 (15.4) 1.3 (15.3) <0.001 <0.01
Triglycerides (mg/dl)
Baseline 133.3 (78.2) 133.3 (78.0) 135.9 (72.8)
% change −4.3 (36.9) −5.5 (36.9) −0.9 (36.9) 0.02 <0.01
ApoA1 (g/liter)
Baseline 1.47 (0.24) 1.49 (0.24) 1.47 (0.24)
% change −0.2 (11.2) 0.7 (11.2) −0.4 (11.2) NS NS
ApoB (g/liter)
Baseline 0.91 (0.22) 0.91 (0.20) 0.91 (0.20)
% change −2.9 (15.9) −0.5 (15.9) 1.4 (15.9) <0.001 NS
J Clin Endocrinol Metab, 2011; 96:3067-3077
“The magnitude of changes in lipids and blood pressure are consistent with decreases secondary to the observed weight loss.”
“…increase in HDL and decrease in triglycerides among pts treated with lorcaserin 10 mg BID were associated with favorable changes in the use of
medications to treat dyslipidemia.”
BLOOM-DM Study Randomized, Placebo-controlled Clinical Trial of Lorcaserin for
Weight Loss in Type 2 Diabetes Mellitus: The BLOOM-DM Study
604 obese or overweight patients with T2DM treated with metformin (91.7%), a SFU (50.2%), or both (41.9%) HgA1c 7-10% (mean 8%)
Randomized 1:1:1 to placebo, lorcaserin 10 mg QD, lorcaserin 10 mg BID with lifestyle counseling
Approximately 54% women
Mean age 53 yr
Obesity, 2012;20:1426-1436
Randomized Placebo‐Controlled Clinical Trial of Lorcaserin for Weight Loss in Type 2 Diabetes Mellitus: The BLOOM‐DM Study
Obesity. 2012; 20:1426-1436
37.5%
44.7%
16.1%16.3%
18.1%
4.4%
4.5% (4.7 kg)
5.0% (5.0 kg)
1.5% (1.6 kg)
BLOOM-DM StudyChange in glycemic parameters by study week
Summary of Lorcaserin TrialsResults at 52 weeks
Study Design Subjects,N
Durationweeks
Primary outcomes Lorcaserin10 mg daily
Lorcaserin10 mg twice
daily
Placebo
BLOOM RC, DB 3182 104 Mean % weight loss 5.81(0.16) 2.16(0.14)*
Smith (2010) 5% weight loss (%) 47.5 20.3*
10% weight loss(%)
22.6 7.7*
% patients completing 52 weeks
55.4 45.1
BLOOM-DM RC, DB 604 52 Mean % weight loss 5.0(0.5) 4.5(0.4) 1.5(0.4)*
O’Neil (2012) 5% weight loss(%)
44.7 37.5 16.1*
10% weight loss(%)
18.1 16.3 4.4*
% patients completing 52 weeks
78.9 66.0 62.1
BLOSSOM RC, DB 4008 52 Mean % weight loss 4.7(6.3) 5.8(6.3) 2.8(6.3)*
Fidler (2011) 5% weight loss(%)
40.2 47.2 25.0*
10% weight loss(%)
17.4 22.6 9.7*
% patients completing 52 weeks
59.0 57.2 52.0
Ann Pharmacotherapy 2013;47:1007
Lorcaserin Summary: Lorcaserin
Non-diabetics Weight loss 5.8 kg vs 2.2 kg placebo (Net 3.6 kg)
Greater proportion of patients achieve >5% and >10% weight loss
Patients who did not lose at least 5% of baseline body weight by week 12 were unlikely to achieve this at one year
Modest reduction in triglycerides and apo B, increase in HDL-C which trends to baseline at 2 years
Most frequent AEs: headache, nausea, dizziness No increase in valvulopathy vs placebo
Summary: Lorcaserin
Diabetics Weight loss 4.7-5.0 kg vs 1.6 kg placebo (Net 3.1-3.4 kg)
Greater proportion of patients achieve >5% and >10% weight loss
Only HDL-C statistically significant change (Net 3.6%) Improved glycemic control Most frequent AEs: headache, nausea, dizziness No increased valvulopathy vs placebo
Lorcaserin
PHENTERMINE
Phentermine
Most widely prescribed anti-obesity drug
Regulatory environment at the time of its approval Generic status (reduced incentive for further
research) Lack of data on weight loss and metabolic effects
of monotherapy for >1 year
Phentermine
Phentermine
Class of agent • Short-term (12 week) weight-management agent
Mechanisms of action • Sympathomimetic amine related to amphetamine (not considered an amphetamine), but with minimal abuse potential, approved 1959
• Noradrenergic effects• Minimal dopaminergic, no serotonergic effects• Increase in satiety• No appreciable effect on energy expenditure
Potential adverse effects • Palpitations, tachycardia, increase in BP, tremor, diaphoresis, overstimulation of CNS (restlessness, dizziness, insomnia, euphoria, dysphoria, psychosis), headache, dry mouth, dysgeusia, constipation, urticaria, impotence and changes in libido
JCL, 2013;7:304-383
Phentermine
Effects on weight reduction and safety of short-term phentermine administration in Korean obese people
68 relatively healthy overweight and obese Korean adults with BMI>25 kg/m2
14-week placebo controlled trial (2-week run-in phase) Phentermine 37.5 mg vs placebo ITT analysis
7.2 kg weight loss vs 2 kg (p<.001) Completer analysis (36 patients)
7.5 kg weight loss vs 3 kg
Yonsei Med J. 2006;47:614-625
Phentermine
Effects on weight reduction and safety of short-term phentermine administration in Korean obese people
In “completers” phentermine expected to produce
4.5 kg (15%) weight loss 20 mg/dl (10%) reduction in total cholesterol 45 mg/dl (35%) reduction in triglycerides 15 mg/dl (15%) reduction in LDL-C Minimal change (2%) in HDL-C
Yonsei Med J. 2006;47:614-625
PHENTERMINE/TOPIRAMATEEXTENDED RELEASE
Phentermine/Topiramate ER
Topiramate CR
Class of agent • Antiepileptic drug• Migraine prophylaxis drug
Mechanisms of action • Unknown • Sulfamate-substituted monosaccharide
neurostabilizer via modification of excitatory voltage-activated sodium and calcium channels, antagonism of alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid kainite receptors, and ehancement of gamma-aminobutyric acid receptor-mediated inhibitory currents
Potential adverse effects • Potentially teratogenic• Difficulty with concentration, memory,
cognition, psychomotor slowing, mood changes with nervousness, anxiety and depression
• Risk of suicidal ideation
JCL, 2013;7:304-383
Phentermine/Topiramate ER
Topiramate CRPotential adverse effects (continued) • Secondary angle glaucoma
• Laboratory abnormalities: bicarbonate, decreased phosphorous, increased alkaline phosphatase, decreased potassium, hyperammonemia with encephalopathy
REMS Program OverviewFDA has required a Risk Evaluation and Mitigation Strategy (REMS) so that healthcare providers can be informed about the increased risk of teratogenicityPurposeThe purpose of the REMS is to inform prescribers and females of reproductive potential (FRP) about the increased risk of congenital malformations, specifically orofacial clefts, in infants exposed to PHEN/TPM during the first trimester of pregnancy
JCL, 2013;7:304-383
Phentermine/Topiramate ERDosage and Administration
• Take once daily in morning. Avoid evening dose to prevent insomnia.• Recommended dose: PHEN/TPM 3.75 mg/23 mg daily for 14 days; then increase to 7.5 mg/46 mg
daily.• Discontinue or escalate dose (as described) if 3% weight loss is not achieved after 12 weeks on 7.5
mg/46 mg dose.• Discontinue PHEN/TPM if 5% weight loss is not achieved after 12 weeks on maximum daily dose of
15 mg/92 mg.• Discontinue 15 mg/92 mg dose gradually (as described) to prevent possible seizure.• Do not exceed 7.5 mg/46 mg dose for patients with moderate or severe renal impairment or patients
with moderate hepatic Impairment.
Supplied as capsules: (phentermine mg/topiramate mg extended-release)• 3.75 mg/23 mg (dose titration only)• 7.5 mg/46 mg• 11.25 mg/69 mg (dose titration only)• 15 mg/92 mg
Phentermine/Topiramate ER
Clinical Trials
EQUIP
CONQUER
SEQUEL (extension phase of CONQUER)
EQUIP TrialControlled-release Phentermine/Topiramate in Severely Obese Adults: A Randomized Controlled Trial (EQUIP)
56 week trial N=1267
BMI>35 kg/m2
TG<200 mg/dl BP<140/90 mmHg Fasting glucose <110 mg/dl
Randominzed 2:1:2 (placebo, PHEN/TPM ER 3.75/23 mg, PHEN/TPM ER 15/92 mg) with lifestyle counseling
Obesity. 2012;20:330-342
EQUIP TrialBaseline values
Variable Placebo PHEN/TPM ER3.75/23
PHEN/TPM ER15/92
LDL-C, mg/dlNMean (s.d.)
512121.3 (32.02)
240122.5 (32.96)
511119.8 (30.06)
HDL-C, mg/dlNMean (s.d.)
51349.5 (13.09)
24050.2 (11.20)
51149.8 (11.72)
TC, mg/dlNMean (s.d.)
513194.7 (36.36)
240196.1 (36.08)
511192.5 (33.77)
TG, mg/dlNMean (s.d.)
513118.8 (39.20)
240116.7 (40.12)
511114.0 (37.24)
Controlled‐Release Phentermine/Topiramate in Severely Obese Adults: A Randomized Controlled Trial (EQUIP)
Obesity. 2012;20:330-342
• Significant weight loss occurred early
• Patients treated with 15/92 lost 8-10% of BW after 12 weeks of treatment
Controlled-release PHEN/TPM CR in severely obese adults: A randomized controlled trial (EQUIP)
Obesity. 2012;20:330-342
Variable Placebo PHEN/TPM CR 3.75/23 PHEN/TPM CR 15/92
N LS mean % change
N LS mean % change
P value vs. placebo
N LS mean % change
P value vs. placebo
P value vs. 3.75/23
TC (%) 479 -3.5(-4.7,-2.2)
230 -5.4(-7.1,-3.7)
0.0502 486 -6.0(-7.3,-4.8)
0.0014 0.5432
LDL-C (%) 478 -5.5(7.4,-3.7)
230 -7.7(-10.3,-5.2)
0.1338 486 -8.4(-10.2,-6.5)
0.0157 0.6584
HDL-C (%) 479 0(-1.6,+1.6)
230 0.5(-1.7,+2.7)
0.7057 486 3.5(1.9,5.1)
0.0005 0.0158
TG (%)
479 9.1(4.7,13.5)
230 5.2(-0.8,11.2)
0.2639 486 -5.2(-9.6,-0.8)
0.0001 0.0027
ITT LOCF
CONQUER Trial Effects of low-dose, controlled-release, phentermine plus topiramate
combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomized, placebo-controlled, phase 3 trial
N=2487, 70% women, mean age 51 yr Mean BMI: ~36 kg/m2
Randomized 2:1:2 (placebo, PHEN/TPM CR 7.5/46 mg, PHEN/TPM CR 15/92 mg)
Baseline Lipids Total cholesterol: 205 mg/dl LDL-C: 124 mg/dl HDL-C: 50 mg/dl Triglycerides: 159 mg/dl
Effects of phentermine plus topiramate on bodyweight
Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomized, placebo-controlled, phase 3 trial
Lancet.2011;377:1341-1352
Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial
Sequel Study Two-year sustained weight loss and metabolic benefits with controlled-
release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study
CONQUER extension study Patients continued with the original treatment to which they were randomized for
additional 52 weeks
866 eligible patients: 676 (78%) enrolled 85.5% on 15/92 79.4% on 7.5/46 69.4% on placebo
84% completed extension phase
Retained original endpoints
Am J Clin Nutr. 2012;95:297-308
SEQUEL Study: Mean (95% CI) percentage weight loss from baseline to week 108.
Garvey W T et al. Am J Clin Nutr 2011;95:297-308
Percentages (and 95% CIs) of subjects achieving ≥5%, ≥10%, ≥15%, or ≥20% weight loss from baseline to week 108 (ITT-LOCF).
Garvey W T et al. Am J Clin Nutr 2011;95:297-308
Effects of PHEN/TPM CR on cardiometabolic variables
Garvey W T et al. Am J Clin Nutr 2011;95:297-308
SEQUEL Study Summary
Beneficial therapeutic effects of PHEN/TPM CR were sustained during a 2-year period.
Improvement in cardiometabolic variables
Statistically significant improvements in triglycerides and HDL-C on active therapy 7.5/46 and 15/92 mg.
Placebo-treated patients (net 17.2% increase LLT) 20.3% increased #LLT 31.5% decreased #LLT
PHEN/TPM CR (net 5.2% and 4.7% increase LLT) Increase in #LLT: 11.1% (7.5/46) and 10.5% (15/92) Reductions in #LLT: 5.9% (7.5/46) and 5.9% (15/92)
Garvey W T et al. Am J Clin Nutr 2011;95:297-308
SEQUEL Study Summary
Beneficial therapeutic effects of PHEN/TPM CR were sustained during a 2-year period.
Improvement in cardiometabolic variables
Statistically significant improvements in triglycerides and HDL-C on active therapy 7.5/46 and 15/92 mg.
Treatment effects on lipids may be confounding results from changes in medications.
Placebo-treated patients more likely to require increase in lipid lowering therapy (net 17.2% increase LLT) vs. active therapy patients (net 5.2% and 4.7% increase LLT)
Garvey W T et al. Am J Clin Nutr 2011;95:297-308
ORLISTAT
OrlistatOrlistatClass of agent • Weight management agent approved in 1999
• Not a controlled substance
Mechanism of action • Reversible inhibitor of gastrointestinal lipases (lumen of stomach and small intestine)
• Forms covalent bond with active serine residue site of lipases
• TG not hydrolyzed into absorbable FFA and are excreted undigested
Potential adverse effects • Oily discharge from the rectum• Flatus with discharge• Fecal urgency, fatty/oily stool, oily anal evacuation• Increased defecation• Fecal incontinence• May increase risk of cholelithiasis, esp. if substantial
weight loss• May increase risk of oxalate nephropathy• Rare reports of severe liver injury with hepatocellular
necrosis or acute hepatic failure resulting in Tx or death
JCL, 2013;7:304-383
OrlistatPotential drug interactions • May decrease cyclosporine levels
• May decrease fat-soluble vitamins (patients should take daily MVT with A, D, E, K, and beta-carotene)
• May reduce levothyroxine levels• May enhance warfarin effect if vitamin K
absorption is diminished
Administration • One 120 mg capsule three times a day with each main meal containing fat (during or up to 1 hour after the meal)
• Vitamin supplement should be taken at least 2 hours before or after the administration of orlistat, such as at bedtime
• Cyclosporine should be administered 3 hours after orlistat
• Levothyroxine and orlistat should be taken at least 4 hours apart
JCL, 2013;7:304-383
Am J Clin Nutr 2004;80:1461-1468
Orlistat Changes in body weight and serum lipid profile in obese
patients treat with orlistat in addition to a hypocaloricdiet: a systematic review of randomized clinical trials
283 citations, 28 eligible RCTs Obese individuals with
Low CVD risk, n=15 Type 2 DM, n=5 High CVD risk with additional risk factors, n=8
17 studies reported data for one-year comparison orlistat vs. placebo (10,041 patients)
Clinically significant weight loss in 1-y studies.n, number of events; N, total sample size; RCT, randomized controlled trial; RR, relative risk
Am J Clin Nutr 2004;80:1461-1468
Mean weight loss in 1-y studies
Am J Clin Nutr 2004;80:1461-1468
Variable Obese, low-risk patients
Diabetes patients Obese, high-risk patients
No. studies(# pts.)
WMD, OL-PL(95% CI)
No. studies(# pts.)
WMD, OL-PL(95% CI)
No. studies(# pts.)
WMD OL-PL(95% CI)
Totalcholesterol(mmol/L){mg/dl}
5(2679) -.32(-0.39,-0.25)
{-12}*
4(1729) -0.37(-0.47,-0.26)
{-14}*
2(908) -0.24(-0.41,-0.07)
{-9.3}*
LDL-C(mmol/L){mg/dl}
5(2679) -0.25(-0.31,-0.19)
{-9.7}*
4(1729) -0.25(-0.35,-0.15)
{-9.7}*
2(908) -0.19(-0.30,-0.09)
{-7.3}*
HDL-C(mmol/L){mg/dl}
4(1799) -0.03(-0.06,-0.01)
{-1.2}
4(1729) -0.03(-0.05,-0.01)
{-1.2}*
1(376) -0.02(-0.06.-0.02)
{-0.78}
TG(mmol/L){mg/dl}
3(1581) 0.00(-0.17,-0.16)
4(1729) -0.20(-0.35,-0.05)
{-18}*
1(376) 0.11(-0.1,0.32)
{9.7}
Changes in body weight and serum lipid profile in obese patients treated with orlistat in addition to hypocaloric diet: a systematic review of randomized clinical trials
Am J Clin Nutr 2004;80:1461-1468
Risk Factor Orlistat120 mg TID
Placebo
Total cholesterol -7.02% -2.03
LDL-cholesterol -11.66% -3.85%
HDL-cholesterol +5.92% +7.01%
Triglycerides +3.64% +1.30%
Pooled data from 5 clinical trials: Mean change in risk factors at 4-year treatment for population as a whole
XENICAL, Prescribing Information
Orlistat Conclusions
Orlistat produces a more robust reduction in LDL-C and less reduction in TGs relative to other weight loss agents
Similar lipid effects of orlistat in XENDOS trial for prevention of new onset diabetes (-37.3%, p=0.0032) in obese subjects with IGT observed out to 4 years
Individual clinical trials may report greater lipid improvements than the modest changes often seen in meta-analyses
JCL 2013;7:304-383Diabetes Care 2004;27;155-161
ANTI-OBESITY DRUGS IN DEVELOPMENT
BUPROPION SR/NALTREXONE SR
Bupropion BupropionClass of agent • Indicated for treatment of major
depressive disorder, smoking cessation, seasonal affective disorder
Mechanisms of action • Closely resembles the structure of diethylpropion, an appetite suppressant with minimal CNS effects
• Relatively weak dopamine and norepinephrine reuptake inhibitor that increases activation of the POMC neurons in the brain to decrease food intake and increase energy expenditure
• Does not inhibit MAO or re-uptake of serotonin
Contraindications and cautionary use • Seizure disorder• Current or previous dx of anorexia or
bulimia• Abrupt discontinuation of alcohol or
sedatives• Concurrent administration of MAO
JCL, 2013;7:304-383
NaltrexoneClass of agent • Competitively binds to opioid receptors in the CNS
• Opioid antagonist used for treatment of alcohol dependence and for the blockade of the effects of IV administered opioids, reducing the physical dependence to morphine, heroin and other opioids,as well as alcohol
Mechanisms of action • Blocks the negative feedback mechanism or self-down-regulation of POMC neurons (via neuropeptides Y and agouti-related protein which increase energy balance by increasing food intake and decreasing energy expenditure)
• Allows bupropion to yield a longer activation of POMC neurons
Potential adverse effects • Nausea• Hepatocellular injury with excessive doses• In alcoholic patients may cause withdrawal
symptoms (tearfulness, mild nausea, abdominal cramps, restlessness, bone or joint pain, myalgia, nasal symptoms, headache, dizziness, nervousness, fatigue, insomnia, vomiting, anxiety, somnolence, depression, suicidal ideations, suicide attempts)
JCL, 2013;7:304-383
Naltrexone SR/bupropion SR
Combination of sustained-release forms of both naltrexone and bupropion
Proposed mechanism is to affect CNS regulation of appetite and energy expenditure Bupropion is weak inhibitor of dopamine uptake and is thought to
reduce food intake and increase energy expenditure via the POMC system
Naltrexone complements bupropion by blocking the feedback loop that inhibits these specific neurons, amplifying the effects of bupropion
Naltrexone SR/bupropion SR Sentinel phase 3 clinical trials
Contrave Obesity Research program COR-I COR-II COR-Diabetes COR-BMOD
Naltrexone SR/bupropion SR
COR-I 58-week safety and efficacy study Randomized, double-blind, placebo controlled 1742 obese patients without T2DM NB16/360 mg, NB32/360 mg, placebo (1:1:1)
Change in bodyweight Observed least squares mean (SE) percentage change from baseline in bodyweight and number of participants at each visit during 56 weeks. *p<0·0001 compared with placebo.
Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
The Lancet Volume 376, Issue 9741 2010 595 - 605
-6.1%-6.1 KGNet: -4.7 kg
-5.0%
-1.3%-1.4 kg
• Weight loss in active therapy patients began early (week 4)
• Maximum weight loss achieved between 28-36 weeks
COR-IPlacebo NB16 NB32 p value for comparison with
placeboTriglyceridesmg/dl
Baseline 113.4 117.8 115.1
% change -3.1% -8.0% -12.7% 0.0461 <0.0001
HDL-Cmg/dl
Baseline 52.2 52.2 51.8
Change 0.00 -3.5 -3.5 <0.0001 <0.0001
% change 0.8% 7.6% 8.0%
LDL-Cmg/dl
Baseline 119.9 124.9 119.1
Change -3.1 -3.9 -4.3 0.8112 0.4838
% change -0.5% -1.5% -2.0%
The Lancet Volume 376, Issue 9741 2010 595 - 605
COR-II
A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II)
1496 patients without T2DM Randomized 2:1 to NB32:placebo 56 weeks
Obesity 2013;21:935-943
A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity‐related risk factors (COR‐II)
Obesity 2013;21:935-943
COR-IIMeasure Week 28 Week 56
PlaceboN=456
NB32N=825
P value Placebo n=456
NB32N=702
P value
Triglycerides
Baseline 113.4+1.6 119.0+1.6 112.8+1.6 118.9+1.6
% change -1.4% -7.3% 0.007 -0.5% -9.8% <0.001
HDL-C
Baseline 51.4+13.1 51.4+13.3 51.6+12.9 51.8+13.6
change -1.4+0.4 +1.2+0.3 <0.001 -0.9+0.5 +3.6+0.4 <0.001
LDL-C
Baseline 117.1+32.6 119.8+30.2 116.8+32.9 120.5+30.2
change 0.00+1.3 -4.4+0.9 0.004 -2.1+1.3 -6.2+0.9 0.008
Obesity 2013;21:935-943
COR-BMOD
Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: The COR-BMOD Trial
56-week, randomized, placebo-controlled trial Efficacy and safety of NB32 as an adjunct to intensive behavior modification 793 patients without T2DM randomized 1:3 (placebo:NM32)
Obesity.2011;19:110-120
Weight Loss With Naltrexone SR/Bupropion SR Combination Therapy as an Adjunct to BehaviorModification: The COR‐BMOD Trial
Obesity2010;19:110-120
COR-BMODVariable Placebo+BMOD NB32+BMOD P value
Triglycerides(mg/dl)
Baseline 104.6+1.6 111.6+1.6
End point 95.6+1.6 91.4+1.6
% change (95% CI)
-8.5%(-1.37%,-3.0%)
-16.6%(-19.7%,-13.5%)
0.004
HDL-C(mg/dl)
Baseline 55.3+12.9 53.6+13.5
End point 56.9+13.4 58.5+14.1
Change(95% CI)
+0.9(-0.7,+2.4)
+4.1(+3.1,+5.1)
<0.001
% change (95%)
+2.8%(-0.3%,+6.0%)
+9.4%(+7.4%,+11.4%)
<0.001
LDL-C(mg/dl)
Baseline 109.2+27.3 109.5+27.5
End point 117.3+33.2 115.0+30.9
Change (95% CI)
+8.1(+4.0,+12.3)
+5.4(+2.8,+8.1)
0.245
% change (95% CI) +10.0(+5.7%,+14.3%)
+7.1(+4.3%,+9.8%)
0.219
Obesity2010;19:110-120
Naltrexone SR/bupropion SR A multicenter, randomized, double-blind, placebo-controlled study
assessing the occurrence of major adverse cardiovascular events (MACE) in overweight and obese subjects with cardiovascular risk factors receiving naltrexone SR/bupropion SR 32/360 mg (The Light Study)
Primary Outcome Measure Time from treatment period randomization to the first confirmed occurrence of MACE Follow-up 4 years
Secondary Outcome Measures Time to CVD death, nonfatal MI, nonfatal stroke, nonfatal unstable angina requiring hospitalization Time to occurrence of CVD death (fatal MI, fatal stroke) Time to occurrence of MI (fatal or nonfatal) Time to occurrence of stroke (fatal or nonfatal)
Estimated enrollment: 10,400
Study start: June 2012 Estimated completion: July 2017
LIRAGLUTIDE
Liraglutide Analog of the incretin hormone glucagon-like peptide-1 (GLP-1)
Effects of liraglutide in the treatment of obesity: a randomized, double-blind, placebo-controlled study
20-week trial in 564 obese, non-diabetic patients Randomized to one of 4 doses of liraglutide (1.2 mg, 1.8 mg, 2.4 mg, or 3.0 mg),
placebo, or orlistat 120 mg TID 84% completed the trial
Baseline lipids (after run-in) Total cholesterol: 188-195 mg/dl LDL-C: 131-137 mg/dl HDL-C: 49-52 Triglycerides: 115-138 mg/dl
Lancet 2009;374:1606-1616Int J of Obesity 2012;36:843-854
Change in bodyweight Data are mean (95% CI) (ANCOVA estimate) for the intention-to-treat population with the last observation carried forward.
Effects of liraglutide in the treatment of obesity: A randomized, double-blind, placebo-controlled study
The Lancet Volume 374, Issue 9701 2009 1606 - 1616
Percentage of individuals who lost more than 5% and more than 10% of baseline weight at week 20 (intention-to-treat population) *p=0·002 vs placebo. †p<0·0001 vs placebo. ‡p≤0·0001 vs placebo or orlistat.
Effects of liraglutide in the treatment of obesity:A randomized, double-blind, placebo-controlled study
The Lancet Volume 374, Issue 9701 2009 1606 - 1616
Liraglutide Safety, tolerability and sustained weight loss over 2 years with the
once-daily human GLP-1 analog, liraglutide
Int J Obesity 2012;36:843-854
◦ 2-year extension study◦ 564 adults enrolled, 398 entered the extension
study and 268 completed the 2-year trial
Int J Obesity. 2012;843-854
Int J Obesity. 2012;843-854
Results: no effects on fasting lipid concentrations at year 1. Modest increase in HDL-C in open-label extension study at year 2 (p=0.03)
Liraglutide
No effects of liraglutide vs placebo on fasting lipids apparent after year 1
At year 2 HDL-C significantly increased with liraglutide 2.4/3.0 mg vs orlistat (p=0.03)
Trend toward reduction in TGs vs orlistat (p=0.053)
Int J Obesity 2012;36:843-854
Liraglutide Weight maintenance and additional weight loss with
liraglutide after low-calorie-diet-induced weight loss: The Scale Maintenance randomized study
551 non-diabetics entered low calorie diet run-in, 422 participants lost >5% of initial body weight during variable-length run-in period (4-12 weeks) with low-calorie diet 1200-1400 kcal/day
Recommended 150 minute/week of aerobic exercise
Met every other week with RD
Randomized to placebo vs liraglutide 3.o mg daily
Int J Obesity 2013;1-9
Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: The Scale Maintenance randomized study
Int J Obesity 2013;1-9
Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: The Scale Maintenance randomized study
Int J Obesity 2013;1-9
Variable Liraglutide3.0 mgN=207
PlaceboN=206
Est. treatment differences(95% CI), p
Total cholesterolmmol/L{mg/dl}
0.2(0.7) 0.3(0.7) -0.1(-0.2,0.03)
P=0.11{-3.87}
LDL-Cmmol/L
{mg/dl}
0.2(0.6) 0.3(0.6) -0.09(-0.2,0.02)
P=0.11{-3.48}
HDL-Cmmol/L
0.2(0.2) 0.1(0.2) 0.0(-0.03,0.04)
P=0.82
Triglyceridesmmol/L
{mg/dl}
0.0(0.5) 0.1(0.5) -0.11(-0.20,-0.01)
P=0.03{-9.74}
Change from randomization to week 56
SUMMARY: OBESITY DRUGS AND LIPIDS/LIPOPROTEINS
Net weight
loss (kg)
Observed changes (mg/dl) Predicted changes based on weight loss alone (mg/dl)
TC p
LDL-Cp
HDL-Cp
TGp
TC LDL-C HDL-C TG
BLOOM(lorcaserin)
-3.6 -6.4
0.001
+3.2
0.049
NS
0.72
-8.26
<0.001
-7.2 -3.2 -1.28 -4.8
BLOSSOM(lorcaserin)
-2.9 NS NS +1.2<0.001
-4.50.02
-5.76 -2.56 -1.02 -3.84
BLOOM-DM -3.4 NS NS -1.630.005
-10.20.054
-6.84 -3.04 +1.22 -4.56
PHENMONO RX
-4.5 -20 -15 +2 -45 -9 -4 +1.6 -6
EQUIPPHEN/TPM
-10.8 -4.80.0014
-3.50.0157
+1.70.0005
-13.30.0001
-21.6 -9.6 -3.84 -14.4
CONQUERPHEN/TPM
-8.8 -5.90.005
NS +3.950.0002
-26.70.0002
-17.64 -7.84 +1.34 -11.76
Net weight
loss (kg)
Observed changes (mg/dl) Predicted changes based on weight loss alone (mg/dl)
TC p
LDL-Cp
HDL-Cp
TGp
TC LDL-C HDL-C TG
OrlistatLow-riskpatients
-3.86 -12 -9.7 NS NS -7.74 -3.44 +1.38 -5.16
OrlistatT2DM
-2.50 -14 -9.7 -1.2 -18 -5.04 -2.24 +0.90 -3.36
OrlistatHigh-risk patients
-2.04 -9.3 -7.3 NS NS -4.05 -1.80 0.72 -2.7
COR-INB32
-4.7 NA -1.2NS
-3.78<0.0001
-11.0<0.0001
-9.36 -4.12 +1.66 -6.24
COR-IINB32
-4.9 NA -4.10.008
+4.5<0.001
-11.0<0.001
NA -4.7 +4.91 -11.99
COR-BMOS -4.21 NA NS +1.70<0.001
-9.040.004
-8.46 -3.76 +1.50 -10.49
Net weight
loss (kg)
Observed changes (mg/dl) Predicted changes based on weight loss alone (mg/dl)
TC p
LDL-Cp
HDL-Cp
TGp
TC LDL-C HDL-C TG
Liraglutide1 year
-5.8 NS NS +2.71 NS -11.61 -5.16 +2.06 -7.74
LiraglutideSCALE
Maintenance
-5.9 NS NS NS -9.740.03
-11.79 -5.24 +2.10 -7.86
Anti-obesity drugs and lipids/lipoproteins
Difficult to define consistent benefit beyond that achieved by weight loss/exercise alone
Variable effects on lipids/lipoproteins Orlistat: reduction in LDL-C All others: greatest benefit on TG, HDL-C Greater TG reduction with higher baseline levels Greater weight loss required for LDL-C benefit Studies do not always describe changes in lipid
modification drugs
Obesity, adiposity, and dyslipidemia: A consensus statement from the National Lipid Association
Harold E. Bays, MD, FNLA, Peter P. Toth, MD, PhD, FNLA, Penny M. Kris-Etherton, PhD, RD, FNLA, Nicola Abate, MD, Louis J. Aronne, MD, W. Virgil Brown, MD, FNLA, J. Michael Gonzalez-Campoy,
MD, PhD, Steven R. Jones, MD, FNLA, Rekha Kumar, MD, Ralph La Forge, MSc, FNLA and VarmanT. Samuel, MD, PhD
Journal of Clinical LipidologyVolume 7, Issue 4, Pages 304-383 (July 2013)
DOI: 10.1016/j.jacl.2013.04.001